ABSTRACT
Introduction
Anthracycline antibiotics have been of much interest in recent years due to the demonstrated therapeutic value in cancer chemotherapy (1) (2) (3) . The "first generation"anthracycline antibiotics (adriamicin, daunomicyn) have developed over the last decade into major chemotherapeutic agents for the treatment of neoplastic disease in man (5, 6) . Their broad range of antitumor activity, limited to some degree by dosedependent cardiotoxicity, has led to vigorous competition by organic chemists to achieve enchanced therapeutic indices for this series of naturally-occurring antibiotics. Several hundred semisynthetic modifications of the natural anthracycline antibiotics have been carried out. Some of these new agents showed good antitumor properties and reduced cardiotoxicity. Epirubicin is a stereoisomer of doxorubicin in which the hydrixil droup in the C-4' position of the amino sugar is epimerized.
Utilisation of polymer carrier of the cytotoxic substances is one of the contemporary approaches for successful modulation of the pharmacokinetics and pharmacodynamics of the antitumor substances. The bounding of the cytotoxic compounds to the macromolecular biopolymer carried decreases its fast penetration in cells, with leads to localization of the impact in tissue with strengthen metabolism and good vascualization. Such carrier system is convenient in the case when cytotoxic drug remain bound to the carrier during the stay in thecentral pharmacokinetic compartment and it is released gradually in tumor and weaker in another normal tissue. The biopolymer chitosan is one of the potential carriers of the conventional cytostatics and anthracycline antibiotics in particular.
In the present study preparation and antileukemic activity of the conjugate of epirubicin with chitosan has been investigated.
Materials and Methods
Chitosan from crab shells Aldrich Chem. Company; Epirubicin from Farmacia&Upjonh.
A Perkin-Elmer Lambda2 spectrophotometer with 1 cm cuvette was utilized to obtain the UV-Vis spectra and Perkin-Elmer FT-IR spectrophotometer using KBr tablets for the IR-spectra. Oxidation of chitosan A reaction mixture obtained by the addition of 20 ml 0.25 M periodic acid to 1 g of chitosan was continuously stirred in a vassel protected from light at room temperature for 6 hours. After completion of the reaction, the oxidized chitosan was washed with distilled water until pH 6.0 was obtained.
Preparation of the epirubicin-chitosan conjugate
To a mixture of 100 mg oxidized chitosan in a 0.1 M phosphate buffer pH 7.5, 140 mg epirubicin was added with rapid stirring. The rection was allowed to proceed 12 hours. The conjugate obtained was washed with destilled water, 5 % sodium chloride and destiled wateradain to remove unreacted products.
The amount of epirubicin bound to the chitosan matrix was determined spectrophotometrically as a 0.002 % solution in 20 % acetic acid according to the formula: N = ∆A 500 .M/c. ε .10 Where: N denotes the number of epirubicin residues, bound to chitosan, ∆A is the absorbtion defference of the sample at 500 nm, M-the molecular weight of the chitosan, c-the sample concentration and ε -the molecular extinction coefficient of antibiotic used.
Biological tests
The biological activity of the conjugate obtained was twstwd against Bacillus subtilis ATCC 6633 by diffusion in agar (18) .
The in vivo studies were performed in hybrid BDF 1 mice. The antileukemic activity was studied on ascitic P 388 lymphocytic leukemia and L1210 lymphoid leukemia with a transplantation dose of 1x10 6 tumor cells, intraperitoneally. Epirubicin and its original conjugate with chitosan were introduced intraperitoneally, once a day, on the first, fourth and eighth day after the tumor transplantation.
The antileukemic activity was assessed by use of the criterion T/C %, where T was the mean survival time (MST, days) of the drug-treated mice, bearing P 388 leukemia or L1210 leukemia and C -the mean survival time ( MST, days ) of untreated control animals.
Results and Discussion
The conjugate was produced by a reaction of activated chitosan and epirubicin in two stages. First, the chitosan matrix was oxidized with periodic acid. The resulting oxidized chitosan had adjacent aldehyde groups in some parts of the molecule. This oxidized chitosan can react with the primary 3'-amino group of daunosamine of the antibiotic (Fig. 1) . The resolting epirubicin-comjugate was studied spectroscopically. In the IR-spectra of the conjugate the typical absorption bounds of the anthraquinone ring of the antibiotic are seen: 1705 cm -1 (COCH 3 ), 1600-1590cm -1 (CO-quinone at C-5 and C-12) as well as the characteristic absorbtion bands of the chitosan at 1400 cm -1 . The appearance of new bands at 1540 cm -1 and 3440 cm -1 of IR-spectra of the epirubicin-chitosan conjugate leads to the suggestion that the amino-group of sugar unit of antibiotic has involved preferentialy in bound formation.
The quantity of the bound antibiotic was evaluated using the spectra of epirubicinchitosan conjugate in 20 % acetic acid. In this assay, were used the fact that in low pH chitosan is soluble in water and the molar extinction coefficient of the antibiotic. Thus, the bound epirubicin were evaluated as 315 residues or 22.5 %.
The biological activity of the conjugate were evaluated against Bacillus subtilis T -survival time of treated mice (days) C -survival time of control mice (days) Significant antileukemic effect at T/C > 125 % was accepted.
AT6633. The obtained data revealed that the conjugate preserves almost fully the antibacterial activity of free epirubicin.
The in vivo studies were performed in hybrid BDF 1 mice. The antileukemic activity was studied in lymphocytic leukemia P 388 andlymphoid leukemia L1210. The results are presented in Table. As seen in the Table, the conjugate has considerable antileukemic effect against P 388 leukemia in a wide range of concentration: from 0.5 to 8.0 mg/ e antileukemic activity of 197.2 % for 2.0 mg/ml.ml, and T/C varing between 125.1 % and 371.5 %. Free epirubicin has maximally antileukemic activity of 197.2 % for 2.0 mg/ml.
As can be seen in the against L1210 leukemia in concentration from 1.0 to 8.0 mg/kg and the T/C varing from 126.7 and 342.1 %. Free epirubicin has a moderate antileukemic activity of 179.0 % for 2.0 mg/ml.
The obtained data revealed that the conjugate of epirubicin with chitosan shoved lower toxicity, higer antitumor effect and significant greater therapeutic spectrum.
In view of the high molecular weight of chitosan may be assumed that the epirubicin-chitosan conjugate is biologically active compound with putative depot-effect of releasing of the active intercalator.
